Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.
 

 
By Jeffrey Bouley, DDNews Chief Editor
Multiple Myeloma Research Foundation announces six new clinical trials in 2014, and Cellectar Biosciences announces IND for relapsed or refractory multiple myeloma drug
 
By Lloyd Dunlap, DDNews Managing Editor
With some tinkering, MIT chemists recruit anthrax to deliver anti-cancer drugs
 
Guest Commentary: Developing humanized cancer models for cost-effective and productive cancer drug discovery
By Dr. Jean-Pierre Wery, CrownBio
Oncology drug discovery faces one of the highest attrition rates for drug candidates in the development pipeline, largely due to efficacy issues. More relevant clinical models, ones that better reflect cancer heterogeneity and disease progression, could address this problem.
 
By Lloyd Dunlap, DDNews Managing Editor
FDA submission reinforces commitment to addressing significant unmet needs for patients with acute lymphoblastic leukemia, an aggressive cancer with limited treatment options
 
DDNews Cancer Research Exclusive: Turning an eye to TERT
By Kelsey Kaustinen, DDNews Senior Editor
As part of the TCGA initiative, researchers have discovered multiple cases of missing chromosomes in chromophobe renal cell carcinoma, as well as rearrangements in the promoter region of the TERT gene
 
 
 
 
 
Millennium, Presage ink research agreement
May 2012
SHARING OPTIONS:

SEATTLE—A new cancer research agreement was established in April between Presage Biosciences and Millennium: The Takeda Oncology Company. Under the agreement, Millennium will gain access to Presage's proprietary technology platform for the non-clinical identification of effective novel drug combinations in solid tumors, for which Presage will be entitled to upfront fees and research funding, as well as development and regulatory milestones based on the identification of successful drug combinations. Specific financial details were not disclosed.  
 
"Presage's technology platform allows us to obtain in-depth non-clinical in-vivo data that is typically difficult to gather by conventional approaches. It is our hope that the Presage platform will help us to more rapidly and accurately prioritize our development of novel combinations," Dr. Joseph B. Bolen, chief scientific officer at Millennium, said in a press release.
 

Back







CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.